Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
NMRA.US
id: 1490
Neumora Therapeutics (NMRA) IPO Misrepresentation Case
S.D. New York
Court1:25-cv-01072
Case number09/15/2023
Class period Start12/30/2024
Class period End04/07/2025
Lead Plaintiff motion deadline- $NMRA investors filed a lawsuit against Neumora Therapeutics, alleging the company misled shareholders about the effectiveness of its lead drug, Navacaprant, and the risks associated with its clinical trials.
- On January 2, 2025, Neumora revealed that its Phase 3 KOASTAL-1 study failed to show significant improvements over a placebo. Following this, $NMRA dropped 88.7%.
- $NMRA investors can join this case to be notified about potential recovery.
Case Details:
Between September 15, 2023, and January 2, 2025, Neumora conducted its IPO, raising over $250 million, and assured investors that Navacaprant, its leading drug candidate for major depressive disorder (MDD), had strong Phase 2 trial results and high prospects for Phase 3 success.
The company claimed that the Phase 2 trial showed positive response rates and positioned Navacaprant as a breakthrough treatment. However, Neumora failed to disclose key risks, including changes in trial criteria, small patient sample sizes, and demographic imbalances, which made the Phase 2 data unreliable for predicting Phase 3 results.
On January 2, 2025, Neumora announced that KOASTAL-1 failed to meet both its primary and secondary endpoints, showing no significant improvement over a placebo. The company admitted that results varied dramatically based on patient gender, an issue that was not disclosed before the IPO.
Following this news, $NMRA collapsed 88.7%, wiping out nearly all of its post-IPO value.
Based on these events, $NMRA investors filed a lawsuit against Neumora Therapeutics, claiming the company:
- It misled investors about the reliability of its Phase 2 trial results and the likelihood of Phase 3 success.
- It failed to disclose critical risks, including data limitations and demographic imbalances, that made its projections unreliable.
Investors believe Neumora misrepresented the strength of Navacaprant’s clinical trials.
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose
Suspected Party
Directors,
Management,
Investment Bank
Security Type
Stocks
Trade Direction
Long
Shock Event Date
01/02/2025
Filing date
02/06/2025
Lead Plaintiff Deadline
04/07/2025